Artiam Bio is focused on developing new medications by targeting the CB1 receptor

Artiam Bio is Pioneering CB1 Therapeutics

Using innovative science, passion and persistence, Artiam Bio is developing novel compounds and sophisticated strategies, for targeting the CB1 receptor. Our pipeline of compounds have the potential to treat Non-alcoholic steatohepatitis (NASH), Cannabis Use Disorders (CUD) and Prader-Willi Syndrome (PWS); three major indications that have sizeable patient populations and at present, no FDA approved therapies.

Our vision is to fully harness the potential of CB1 therapeutic technology to improve the lives of people living with limited or inadequate treatment options.

At Artiam Bio, our leadership team is focused on delivering transformative, highly differentiated therapies for disease-specific targeted indications. Our drug discovery programs are led by experts in chemistry, cannabinoid pharmacology, clinical research, and biotechnology. We are seamlessly working together to provide a responsive, adaptable approach with the ability to further explore and optimize tailored solutions to each disease area of interest.

We measure our success not only by our business performance but by our standards of scientific excellence and the meaningful benefits we bring to improving patient health and wellbeing.

Artiam Bio Management Team

Ronnie Maitra, PhD, Founder & President

Dr. Maitra founded Artiam Bio based on technology that was developed in his laboratory for over a decade. An expert in CB1 receptor pharmacology, he was instrumental in developing and testing strategies to safely target the CB1 receptor for various diseases. Dr. Maitra received his PhD in Pharmacology & Toxicology from Dartmouth Medical School and completed his postdoctoral training at NIH.

Herb Seltzman, PhD, Vice President

Dr. Seltzman has over 40 years of experience as a medicinal chemist with expertise in cannabinoid research. Dr. Seltzman is presently pursuing commercialization of this exciting technology, which he jointly developed with Dr. Maitra. Dr. Seltzman is credited with over 200 publications, presentations and book chapters. He received his PhD from the University of Pittsburgh and completed his postdoctoral training with Dr. Ivy Carroll at RTI prior to joining the institute full-time, where he served with distinction for over 40 years prior to his recent transition to emeritus faculty.

Scientific Advisors

Brad Walters MD, PhD, MBA

Former CMO – RTI International, background in VC, biotechnology startups and Phase I, II clinical trials. PhD from University College London, MD from Harvard, MBA from UNC-CH.

Ryan Vandrey PhD

Professor – Johns Hopkins University. Research focuses on the behavioral pharmacology of cannabis, particularly human laboratory studies on cannabis addiction and pharmacology. KOL in clinical pharmacology of cannabis use disorders. PhD from University of Vermont.

Yong-Hui Jiang MD, PhD

Professor and Chief of Medical Genetics, Yale University. Physician scientist active both in basic research and clinical practice. Research interests are to uncover the genetic and epigenetic bases of neurodevelopmental disorders or rare diseases with neurodevelopmental defects including Prader Willi Syndrome (PWS).

Mike Statnick, PhD

Pharma executive with 20+ years of experience in metabolic disorders, addiction and mood disorders. PhD from Southern Illinois University. Held leadership positions at Eli Lilly, Recursion Pharmaceuticals and Novo Nordisk.

Arun Sanyal, MD

Professor of Gastroenterology, Hepatology & Nutrition at Virginia Commonwealth University. Chair of NIH NASH Clinical Research Network. Distinguished KOL with over 500 research publications.

Key Members

Robert Willette, PhD

BOD, Chief Technology Advisor. Ex-GSK lead in metabolic diseases. Additional background in neuropharmacology.

Joshua Higgin PhD, JD

Legal services including patent and freedom to operate analyses, corporate counsel. PhD from University of Wisconsin, JD from Wake Forest.

Marilyn Thompson, BA

CFO & Financial Services. Thirty plus years of experience in corporate finance.